InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,388.34
(
0.82%
)
US TECH 100
18,223.60
(
0.93%
)
Dow Jones
39,513.75
(
0.40%
)
Brent Oil
81.11
(
-0.61%
)
Bitcoin
59,128.09
(
-0.38%
)
Post# of 234
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Tina

Send PM Follow Ignore
Followers 618
Posts 76741
Boards Moderated 15
Alias Born 01/30/2006

Tina

Re: DewDiligence post# 26

Saturday, 06/24/2006 8:05:38 PM

Saturday, June 24, 2006 8:05:38 PM

Post# of 234
Thank you for the board. I promise to do it justice =)

However, MACUGEN is administered 4 times a year by an injection placed directly into the eye. Evison on the other hand, is administered intravenously into the arm.

Injections of Macugen are extremely expensive. If Evizon is approved and declared more effective (which I believe it will) then it most certainly will be the primary source of treatment due to the lower costs (insurance companies will jump on it) in which case, GENR's revenues will soar.

Click here to visit:


Disclaimer: http://investorshub.advfn.com/boards/irp.aspx?userid=65709

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up